Last $0.19 USD
Change Today 0.00 / 0.00%
Volume 91.3K
IMUN On Other Exchanges
As of 5:20 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

immune therapeutics inc (IMUN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/7/14 - $1.16
52 Week Low
12/15/14 - $0.08
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

immune therapeutics inc (IMUN) Related Businessweek News

No Related Businessweek News Found

immune therapeutics inc (IMUN) Details

Immune Therapeutics, Inc. focuses on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases, and immune disorders in the United States. The company develops IRT-101, an active immunotherapy systemic administration of methionine-enkephalin that works by stimulating and/or regulating a patient’s immune system against infectious diseases, autoimmune diseases, immune disorders, and tumor cells. It also develops IRT-103, an adaptive immunotherapy for the treatment of various autoimmune diseases, such as Crohn's disease and multiple sclerosis; HIV/AIDS; and cancer. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in December 2014. Immune Therapeutics, Inc. is headquartered in Orlando, Florida.

12 Employees
Last Reported Date: 03/31/14

immune therapeutics inc (IMUN) Top Compensated Officers

Chairman, Chief Executive Officer and Founder
Total Annual Compensation: $341.7K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $60.0K
Chief Science Officer
Total Annual Compensation: $60.0K
Compensation as of Fiscal Year 2013.

immune therapeutics inc (IMUN) Key Developments

Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc

Immune Therapeutics, Inc. announced the signing of the agreement with KRS Global Biotechnology, Inc. for the compounding, packaging and distributing of its naltrexone tablets. The tablets will be compounded for shipment in the United States.

Immune Therapeutics, Inc. Announces Board Changes

Immune Therapeutics, Inc. announced that Vincent Butta, a new director appointed to fill a vacancy, and Edward Teraskiewicz, a director elected at the 2014 annual meeting of shareholders, joined the board on January 13, 2015. Vincent Butta was appointed by the board of directors on January 13, 2015 to fill a vacancy on the board. Mr. Butta is a visionary executive business leader with a 30-year track record in Operations, Executive Management, Technology, Supply Chain Management, Marketing, Sales Management, Brand Creation, Licensing, Digital and Social Media, and Strategic Planning. Two of the board members elected at the 2014 annual meeting of shareholders, Roger Bozarth and Joel Yanowitz, will not join the board in January as agreed as Immune Therapeutics has not yet purchased D&O insurance; however, the company expects that Mr. Bozarth will work with the company in an advisory capacity. Jay Goldstein, a director that was also elected at the 2014 annual meeting, was unable to accept his election to the board as a new position taken by Mr. Goldstein limits his ability to take outside board seats.

Immune Therapeutics, Inc. Announces Executive Changes

Immune Therapeutics, Inc. announced that effective January 13, 2015, Dr. Eugene Youkilis is stepping down from the position of President of Immune Therapeutics, Inc., but will continue to serve as a member of the board of directors of the company. Effective January 13, 2015, Christopher Pearce is stepping down from the position of Chief Operating Officer of the company, but will continue to serve as a member of the board of directors of the company. Effective January 13, 2015, the board of directors of the company formally appointed Seth Elliott as President and Chief Operating Officer of the company. Mr. Elliot has spent more than 15 years as a founder or senior executive of emerging growth and middle market enterprises. He has helped to accelerate corporate growth in diverse markets, on behalf of a variety of companies through economic conditions ranging from boom to bust, developing a rare combination of experience, vision, leadership and business intuition. Mr. Elliott started his position as Chief Strategy Officer of Engagement Media Technologies in 2011.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMUN:US $0.19 USD 0.00

IMUN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMUN.
View Industry Companies

Industry Analysis


Industry Average

Valuation IMUN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNE THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at